The utility of levosimendan in the treatment of heart failure

Annals of Medicine

Volumn 39, Issue 1, 2007, Pages 2-17

  Lehtonen, Lasse ^a   Põder, Pentti ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b ORION CORPORATION   (Finland)

Author keywords

Calcium sensitizer; Efficacy; Heart failure; Levosimendan; Pharmacology; Safety; Therapy

Indexed keywords

4,5 DIHYDRO 6 [4 (4 PYRIDYLAMINO)PHENYL] 3(2H) PYRIDAZINONE; 5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; CALCIUM SENSITIZER; CONTRACTILE PROTEIN; DIURETIC AGENT; DOBUTAMINE; DRUG METABOLITE; INOTROPIC AGENT; LEVOSIMENDAN; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; OR 1855; PIMOBENDAN; PLACEBO; POTASSIUM CHANNEL; TROPONIN C; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG UTILIZATION; EUROPE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEART PROTECTION; HEART RATE; HEART RHYTHM; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HOSPITALIZATION; HUMAN; INDUCED HYPOTENSION; LOADING DRUG DOSE; LUNG CAPILLARY PRESSURE; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; QRS COMPLEX; QT PROLONGATION; REVIEW; SIDE EFFECT; SURVIVAL; SYMPTOM; VASODILATATION;

CARDIOTONIC AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; PYRIDAZINES; STROKE VOLUME; SURVIVAL RATE; TREATMENT OUTCOME; VASODILATION;

EID: 33847028846     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/07853890601073346     Document Type: Review

References (85)

1. Felker GM, O'Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J. 2001;142:393-401.
2. Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology. 2006;104:556-69.
3. Leier CV, Binkley PH. Parenteral inotropic support for advanced congestive heart failure. Prog Cardiovasc Dis. 1998;41:207-24.
4. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541-7.
5. Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation. 2006;113:305-15.
6. Lehtonen LA, Antila S, Pentikainen PJ. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet. 2004;43:187-203.
7. Ver Donck L. Calcium-sensitizing drugs: positive inotropy by enhanced sensitivity of the contractile apparatus to calcium. Cardiovasc Drug Rev. 1996;14:185-212.
8. Lehtonen L. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure. Curr Cardiol Rep. 2000;2:233-43.
9. 2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. J Biol Chem. 1994;269:28584-90.
10. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden I-B. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol. 1995;27:1859-66.
11. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol. 1995;25:794-801.
12. Pagel PS, Harkin CP, Hettrick DA, Warltier DC. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs. Anesthesiology. 1994;81:974-87.
13. Haikala H, Kaheinen P, Levijoki J, Linden IB. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res. 1997;34:536-46.
14. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 1998;98:2141-7.
15. Brixius K, Reicke S, Schwinger RH. Beneficial effects of the Ca(2+) sensitizer levosimendan in human myocardium. Am J Physiol Heart Circ Physiol. 2002;282:H131-7.
16. Udvary E, Papp JG, Vegh A. Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction. Br J Pharmacol. 1995;114:656-61.
17. Pagel PS, McGough MF, Hettrick DA, Lowe D, Tessmer JP, Jamali IN, et al. Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy. J Cardiovasc Pharmacol. 1997;29:563-73.
18. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol. 1997;333:249-59.
19. Pataricza J, Hohn J, Petri A, Balogh A, Papp JG. Comparison of the vasorelaxing effect of cromakalin and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol. 2000;52:213-7.
20. Kersten JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg. 2000;90:5-11.
21. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. The novel calcium sensitizer levosimendan activates the ATPsensitive K+ channel in rat ventricular cells. J Pharmacol Exp Ther. 1997;283:375-83.
22. Kopustinskiene DM, Pollesello P, Saris NE. Levosimendan is a mitochondrial K(ATP) channel opener. Eur J Pharmacol. 2001;428:311-4.
23. Rump AF, Acar D, Rosen R, Klaus W. Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts. Pharmacol Toxicol. 1994;74:24424-8.
24. Boknik P, Neumann J, Kaspareit G, Schmitz W, Scholz H, Vahlensieck U, et al. Mechanisms of the contractile effects of levosimendan in the mammalian heart. J Pharmacol Exptl Ther. 1997;280:277-83.
25. Sato S, Talukder MA, Sugawara H, Sawada H, Endoh M. Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol. 1998;30:1115-28.
26. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res. 1995;77:107-13.
27. Sandell EP, Häyha M, Antila S, Heikkinen P, Ottoila P, Lehtonen LA, et al. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J Cardiovasc Pharmacol. 1995;26 Suppl 1:S57-62.
28. Antila S, Jarvinen A, Honkanen T, Lehtonen L. Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin. Eur J Clin Pharmacol. 2000;56:705-10.
29. Lilleberg J, Sundberg S, Häyha M, Akkila J, Nieminen MS. Haemodynamic dose-efficacy of levosimendan in healthy volunteers. Eur J Clin Pharmacol. 1994;47:267-74.
30. Sundberg S, Antila S, Scheinin H, Häyha M, Virtanen M, Lehtonen L. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals. Int J Clin Pharmacol Ther. 1998;36:629-35.
31. Antila S, Huuskonen H, Nevalainen T, Kanerva H, Vanninen P, Lehtonen L. Site dependent bioavailability and metabolism of levosimendan in dogs. Eur J Pharm Sci. 1999;9:85-91.
32. Pagel PS, Haikala H, Pentikäinen P, Toivonen M-L, Nieminen MS, Lehtonen L, et al. Pharmacology of levosimendan: a new myofilament calcium sensitizer. Cardiovasc Drug Rev. 1996;14:286-316.
33. Takahashi R, Talukder MA, Endoh M. Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium. Eur J Pharmacol. 2000;400:103-12.
34. Szilagyi S, Pollesello P, Levijoki J, Kaheinen P, Haikala H, Edes I, et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol. 2004;486:67-74.
35. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther. 2002;40:465-71.
36. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol. 2002;42:43-51.
37. Antila S, Pesonen U, Lehtonen L, Tapanainen P, Nikkanen H, Vaahtera K, et al. Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. Eur J Pharm Sci. 2004;23:213-22.
38. Antila S, Kivikko M, Lehtonen L, Eha J, Heikkila A, Pohjanjousi P, et al. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. Br J Clin Pharmacol. 2004;57:412-5.
39. Pentikäinen PJ, Antila S, Kivikko M, Sandell E-P, Aalto T, Luomanmäki K, et al. Pharmacokinetics of levosimendan in patients with severe congestive heart failure. J Card Fail. 1999;5 Suppl 1:48.
40. Turanlahti M, Boldt T, Palkama T, Antila S, Lehtonen L, Pesonen E. Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery. Pediatr Crit Care Med. 2004;5:457-62.
41. Jonsson EN, Antila S, McFadyen L, Lehtonen L, Karlsson MO. Population pharmacokinetics of levosimendan in patients with congestive heart failure. Br J Clin Pharmacol. 2003;55:544-51.
42. Remme WJ, van Hoogenhuyze DC, Kruijssen HA, Pieper PG, Bruggeling WA. Preload-dependent hemodynamic effects of milrinone in moderate heart failure. Cardiology. 1992;80:132-42.
43. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1903-12.
44. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H, et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther. 2000;68:522-31.
45. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med. 1998;339:1810-16.
46. Moe GW, Rouleau JL, Charbonneau L, Proulx G, Arnold JM, Hall C, et al. Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan. Am Heart J. 2000;139:587-95.
47. Sundberg S, Lilleberg J, Nieminen MS, Lehtonen L. Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men. Am J Cardiol. 1995;75:1061-6.
48. Sundberg S, Lehtonen L. Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects. Eur J Clin Pharmacol. 2000;55:793-9.
49. Ukkonen H, Saraste M, Akkila J, Knuuti MJ, Lehikoinen P, Någren K, et al. Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther. 1997;61:596-607.
50. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol. 2004;43:2177-82.
51. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation. 2000;102:2222-7.
52. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2003;107:81-6.
53. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196-202.
54. Lehtonen L, Sundberg S. The contractility enhancing effect of the calcium sensitiser levosimendan is not attenuated by carvedilol in healthy subjects. Eur J Clin Pharmacol. 2002;58:449-52.
55. Lilleberg J, Nieminen MS, Akkila J, Heikkila L, Kuitunen A, Lehtonen L, et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J. 1998;19:660-8.
56. De Luca L, Proietti P, Celotto A, Bucciarelli-Ducci C, Benedetti G, Di Roma A, et al. Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. Am Heart J. 2005;150:563-8.
57. Packer M, Colucci WS, Fisher L, Massie BM, Teerlink JR, Young JB, et al. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE-1 study. Abstract. ESC Congress 2003, 30 August-3 September 2003, Vienna, Austria. http://cic.escardio.org/AbstractDetails.aspx?id56596&eevtid51.
58. Packer M. REVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. American Heart Association Scientific Sessions 2005, 13-16 November 2005, Dallas, Texas. Late Breaking Clinical Trials II.
59. Moiseyev VS, Põder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;18:1422-32.
60. Zairis MN, Apostolatos C, Anastasiadis P, Mytas D, Katsaris C, Kouris N, et al. The Effect of a Calcium Sensitizer or an Inotrope or None in Chronic Low Output Decompensated Heart Failure: Results From the Calcium Sensitizer or Inotrope or None in Low Output Heart Failure Study (CASINO). Abstract. Annual Scientific Sessions of the American College of Cardiology, 7-10 March 2004, New Orleans, USA.
61. Mebazaa A, Cohen-Solal A, Kleber F, Nieminen M, Packer M, Pocock S, et al. Study design of a mortality trial with intravenous levosimendan-the SURVIVE study-in patients with acutely decompensated heart failure. Crit Care Med. 2004;8 Suppl 1:P87.
62. Mebazaa A. The SURVIVE-Trial: Comparison of dobutamine and levosimendan on survival in acute decompensated heart failure. American Heart Association Scientific Sessions 2005, 13-16 November 2005, Dallas, Texas. Late Breaking Clinical Trials IV.
63. Toivonen L, Viitasalo M, Sundberg S, Akkila J, Lehtonen L. Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function. J Cardiovasc Pharmacol. 2000;35:664-9.
64. Singh BN, Lilleberg J, Sandell EP, Ylönen V, Lehtonen L, Toivonen L. Effects of levosimendan on cardiac arrhythmia: electrophysiologic and ambulatory electrocardiographic findings in phase II and phase IIII clinical studies in cardiac failure. Am J Cardiol. 1999;83 Suppl 12B:9-11.
65. Lilleberg J, Ylonen V, Lehtonen L, Toivonen L. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scand Cardiovasc J. 2004;38:80-4.
66. Antila S, Honkanen T, Lehtonen L, Neuvonen PJ. The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan. Int J Clin Pharmacol Ther. 1998;36:446-9.
67. Põder P, Eha J, Antila S, Heinpalu M, Planken Ü , Loogna I, et al. Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease. Cardiovasc Drugs Ther. 2003;17:451-8.
68. Antila S, Eha J, Heinpalu M, Lehtonen L, Loogna I, Mesikepp A, et al. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. Eur J Clin Pharmacol. 1996;49:451-8.
69. Harjola VP, Peuhkurinen K, Nieminen MS, Niemelä M, Sundberg S. Oral levosimendan improves cardiac function and hemodynamics in patients with severe congestive heart failure. Am J Cardiol. 1999;83 Suppl 12B:4-8.
70. Põder P, Eha J, Sundberg S, Antila S, Heinpalu M, Loogna I, et al. Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study. J Clin Pharmacol. 2004;44:1143-50.
71. Hosenpud JD, and the oral levosimendan study group, Levosimendan, a novel myofilament calcium sensitizer, allows weaning of parenteral inotropic therapy in patients with severe congestive heart failure. Am J Cardiol. 1999;83 Suppl 12B:9-11.
72. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. ESC Committee for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384-416.
73. Follath F, Hinkka S, Jäger D, Just H, Mitrovic V, Papp JG, et al. Dose-ranging and safety with intravenous levosimendan in low-output heart failure: Experience in three pilot studies and outline of the levosimendan infusion versus dobutamine (LIDO) trial. Am J Cardiol. 1999;83 Suppl 12B:21-5.
74. Nijhawan N, Nicolosi AC, Montgomery MW, Aggarwal A, Pagel PS, Warltier DC. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol. 1999;34:219-28.
75. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIRAMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006;8:105-10.
76. Tritapepe L, De Santis V, Vitale D, Santulli M, Morelli A, Nofroni I, et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. Br J Anaesth. 2006;96:694-700.
77. Jamali IN, Kersten JR, Pagel PS, Hettrick DA, Warltier DC. Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg. 1997;85:23-9.
78. Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation. 2005;111:1504-9.
79. Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M. Duration of the haemodynamic action of a 24-hour infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail 2006 Jul 6; [Epub ahead of print].
80. Barisin S, Husedzinovic I, Sonicki Z, Bradic N, Barisin A, Tonkovic D. Levosimendan in off-pump coronary artery bypass: a four-times masked controlled study. J Cardiovasc Pharmacol. 2004;44:703-8.
81. Siirila-Waris K, Suojaranta-Ylinen R, Harjola VP. Levosimendan in cardiac surgery. J Cardiothorac Vasc Anesth. 2005;19:345-9.
82. Braun JP, Jasulaitis D, Moshirzadeh M, Doepfmer UR, Kastrup M, von Heymann C, et al. Levosimendan may improve survival in patients requiring mechanical assist devices for post-cardiotomy heart failure. Crit Care. 2006;10:R17.
83. Orion Corporation, Results of PERSIST study with oral levosimendan. Company communication June 6, 2006. Available from: http://www. orionennenjakautumista.fi/english/investors/stockreleases.shtml/a05?24526.
84. Kivikko M, Lehtonen L. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. Curr Pharm Des. 2005;1:435-55.
85. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA. 2002;287:628-40.